肠道菌群
糖尿病
发病机制
益生菌
高胰岛素血症
生物信息学
代谢综合征
脂肪肝
医学
生物
免疫学
胰岛素抵抗
内科学
疾病
内分泌学
遗传学
细菌
作者
Lucilla Crudele,Raffaella Maria Gadaleta,Marica Cariello,Antonio Moschetta
出处
期刊:EBioMedicine
[Elsevier]
日期:2023-11-01
卷期号:97: 104821-104821
被引量:22
标识
DOI:10.1016/j.ebiom.2023.104821
摘要
The gut-liver axis plays a prominent role in the pathogenesis and therapy of metabolic diseases such as diabetes. The intestinal specific origin of several hormones that guide both inter- and post-prandial metabolism of carbohydrates and lipids, drives the attention of scientists and clinicians on the gut as a major site to intervene with novel diagnostic or prognostic markers. The role of intestinal ecology in the metabolic syndrome was postulated when gut microbiota was directly connected with inflammation, hyperinsulinemia, and diabetes. There have been several discoveries with the role of gut microbiota and gut-liver axis in diabetes. Also, there are several trials ongoing on the therapeutic efficacy of probiotic administration in diabetes and its complications. Here we point to the metabolic action of microbiota and discuss the actual state of the art on gut microbiota as a novel prognostic biomarker with a putative therapeutic role in diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI